Introduction {#s1}
============

Ultrasound-guided transvaginal follicle aspiration has become the gold standard for oocyte pick-up (OPU) in human *in vitro* fertilization (IVF) over the last 20 years. The technique has proved to be both efficient and safe. ([@DER100C14]; [@DER100C22]). One of the advantages of the technique is that it can be performed under local anaesthesia. Since oocyte retrieval under local anaesthesia can be painful, different methods of analgesia have been evaluated ([@DER100C12]). The most commonly used method is conscious sedation with or without a paracervical block (PCB; [@DER100C11]; [@DER100C5]). This means that the patient has some kind of light intravenous sedation. Studies have suggested superior pain relief with conscious sedation in combination with a PCB compared with sedation alone ([@DER100C10]; [@DER100C17]). However, owing to the fact that patients may experience pain during the procedure, many IVF groups still use general anaesthesia despite OPU then becoming more complicated and expensive since full anaesthesiological service for each procedure is required. Although the best type of analgesia for oocyte retrieval has not yet been established, local anaesthesia in combination with conscious sedation is probably the most frequently used. However, very little attention has been paid to the technical aspects, such as needle design and the effect on pain experience. There are only two published studies where pain experience in relation to the needle diameter has been explored ([@DER100C2]; [@DER100C1]). In these studies, significantly less pain was experienced when the needle was reduced from 15 and 16 gauge to 17 and 18 gauge. It remains unknown whether an even thinner needle might cause less pain when the OPU procedure is performed under local anaesthesia. Reducing the needle diameter too much (\<0.8 mm), however, may be a problem with regard to damage to the oocyte ([@DER100C9]). Another problem with a very thin needle is that it may miss the target, thereby making the retrieval technically more difficult and less efficient. In order to circumvent these problems, a new needle has been designed where only the last 50 mm of the needle is reduced in diameter. Thus, only the part of the needle that penetrates into the tissues is reduced in diameter. In order to determine whether this new needle results in less pain compared with a standard needle (SN), a prospective randomized study was designed.

The aim of this study was to compare the pain experience during oocyte retrieval between a newly designed thinner needle and a thicker SN.

Materials and Methods {#s2}
=====================

A prospective, randomized, comparative, multi-centre study was performed at the Fertility Centre Carlanderska Hospital, Gothenburg, Sweden; Centre for Reproductive Medicine, University Hospital, Malmö, Sweden; Fertility Unit at Karolinska University Hospital, Huddinge, Stockholm, Sweden and the IVF Clinic Falun, Falu Hospital, Falun, Sweden between June and December 2009.

The Ethics Committee at the University of Göteborg approved the study. All patients who were included gave their written informed consent. The study was registered at the ClinicalTrial.Gov, study number NCT00924885.

The patient population consisted of all patients who were going to have oocyte aspiration performed at the four clinics during the study period.

Patients were eligible for randomization if they fulfilled the following criteria: (i) signed the written consent, (ii) had the oocyte aspiration under local anaesthesia and (iii) were Swedish-speaking. The exclusion criteria were as follows: (i) previous participation in the study, (ii) body mass index (BMI) ≥35 and (iii) other contraindications for oocyte aspiration.

Randomization {#s2a}
-------------

Patients were randomized by a nurse on the day of oocyte retrieval, using electronic locally installed randomization programme, to either the reduced needle (RN) group or the SN group. Randomization was 1:1 with optimal allocation according to Pocock\'s minimization technique for sequential randomization ([@DER100C18]). Consideration was given to the woman\'s age, number of previous oocyte aspirations, pre-medication and the number of follicles with an external diameter exceeding 10 mm at the last ultrasound before oocyte aspiration. The patient was blinded to which group she had been randomized into. For practical reasons, the doctor and the nurse were not blinded to patient randomization group.

The study flow chart of patients randomized is shown in Fig. [1](#DER100F1){ref-type="fig"}. Figure 1Flow chart of patients for the study.

Rating of pain {#s2b}
--------------

Rating of pain was performed by self-assessment by means of visual analogue scale (VAS) consisting of a line oriented vertically on a paper with a range from 0 mm (no pain) to 100 mm (unbearable pain) ([@DER100C15]). Immediately after the oocyte aspiration and before the patient had been given the final result of the number of oocytes retrieved, she was asked by a nurse to rate the 'overall pain for the whole procedure'. This was the primary end-point. The nurse only asked the patient to put a mark on the vertical line on the paper with the VAS.

All data were recorded on a case report form, which was transferred manually into an electronic database for analysis. The database was quality-controlled by two individuals who double checked all parameters. They independently measured the marks on the VAS. All data input was done blinded from group allocation.

Ovarian stimulation and oocyte aspiration {#s2c}
-----------------------------------------

Ovarian stimulation was performed using follicle-stimulating hormone or human menopausal gonadotrophin in combination with GnRH agonists or antagonists according to each clinic\'s routines. Dosage was set individually, taking into account age, menstrual cycle length, smoking habits, BMI, the number of pre-antral follicles and, whenever appropriate, the previous response. Ovarian response was monitored by transvaginal ultrasound and serum estradiol when necessary. Oocyte retrieval was carried out 36--38 h after hCG injection ([@DER100C4]). Standard IVF or ICSI was used according to the indication for the treatment.

Transvaginal oocyte retrieval was performed under local anaesthesia (see below) and under guidance of ultrasound with either the RN with an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle (Fig. [2](#DER100F2){ref-type="fig"}) or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle (Fig. [2](#DER100F2){ref-type="fig"}). Both needles were provided by the manufacturer (Vitrolife Sweden AB, Göteborg, Sweden). The puncture procedure was performed according to each clinic\'s standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg. All the physicians (*n* = 13) performing the oocyte retrievals were skilled, had many years of experience and used the same technique. Figure 2Illustration of the distal part of the two needles tested. OD, outside diameter; ID, internal diameter.

Laboratory procedures such as culturing and freezing techniques were performed according to each laboratory\'s standard technique. Embryo transfer was performed on Day 2, 3 or 5 according to each clinic\'s routine.

Sedation and local anaesthesia {#s2d}
------------------------------

Pre-operatively, all patients received paracetamol 1 g (Panodil 1 g; Glaco Smith Kline, Täby, Sweden). All patients had a PCB with 10 ml of 1% (10 mg/ml) lidocaine (AstraZeneca, Södertälje, Sweden) and were given a total dose of 100 mg, using a needle of 0.9 mm diameter and 120 mm length (Mediplast AB, Malmö, Sweden). Additionally, all patients received alfentanil (Rapifen 0.5 mg/ml; Janssen-Cilag AB, Sollentuna, Sweden) 0.25 mg i.v. immediately before the PCB was given. If needed (patient request), a supplementary dose of 0.25 mg alfentanil was given up to three times, and the total dose was recorded.

Secondary end-points {#s2e}
--------------------

Vaginal bleeding during or after the procedure was graded subjectively by the physician as (i) less than normal, (ii) normal or (iii) more than normal. This was considered the second most important parameter.

Aspiration time was measured from the time the first follicle was punctured until the last follicle had been aspirated and the needle withdrawn.

The number of follicles aspirated as well as the number of oocytes, the number of fertilized oocytes, the number of embryos cleaved (of normally fertilized), the number of good quality embryos (=transferred + frozen embryos), the number of embryos transferred and the number of embryos frozen were registered. Clinical pregnancy was defined as gestational sac seen on ultrasound at least 5 weeks after transfer.

Furthermore, secondary end-points were also the patients rating of (i) the maximum pain, (ii) pain they experienced directly after the oocyte aspiration, (iii) 30 min and (iv) 60 min after the procedure.

Sample size calculation and statistical analysis {#s2f}
------------------------------------------------

The primary end-point was the 'overall pain experience', evaluated as described previously. Assuming the mean overall pain in the RN group to be 27 mm (value chosen after analysis of data from a previous study from our group, [@DER100C8]) on VAS, with a standard deviation (SD) of 21.5 mm (based on analysis of data from a previous study [@DER100C8]), 121 patients in each group would be needed to demonstrate a decrease in overall pain of 8 mm (30%) with 80% power and a significance level of 0.05 (two-tailed tests).

Continuous variables were described with mean, SD, median and range and categorical variables as *n* and percent. For comparison between the two groups, Fisher\'s exact test was used for dichotomous variables, Mantel--Haenszel *χ*^2^ test for ordered categorical variables and Mann--Whitney *U*-test for continuous variables. Calculation of confidence interval of differences in means between the two groups for continuous variables was based on the assumption of normality.

All significance tests were two-tailed and conducted at the 0.05 significance level. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Two hundred and fifty-seven (*n* = 257) patients were randomized. Due to practical reasons, 482 patients could not be invited to participate in the study even though they fulfilled the criteria to participate (Fig. [1](#DER100F1){ref-type="fig"}). Three clinics recruited 70 patients and one clinic 47 patients. One hundred and twenty-nine were allocated to the RN group and 128 to the SN group. Furthermore, in the RN group, three patients were excluded due to protocol violations, resulting in 126 assessed per protocol (PP). In the SN group, one patient was excluded after randomization at her own request, and three were excluded due to protocol violations, resulting in 124 assessed PP (Fig. [1](#DER100F1){ref-type="fig"}).

No patient was lost to follow-up.

There were no differences in patient characteristics between the two groups irrespective of whether data were analysed per intention-to-treat (ITT) or PP (Table [I](#DER100TB1){ref-type="table"}). Table IPatient characteristics, given as mean ± SD (range) per protocol populationRN (*n* = 126)SN (*n* = 124)Age34.2 ± 4.7 (24--44)34.4 ± 4.2 (24--43)BMI23.2 ± 3.6 (17--35)23.7 ± 3.4 (19--35)No. of follicles at the last scan before OPU10.7 ± 5.6 (2--40)10.3 ± 4.6 (2--35)Previously performed OPU1.34 ± 1.54 (0--6)1.37 ± 1.81 (0--12)[^1][^2]

Pain rating of OPU {#s3a}
------------------

The overall pain (primary end-point) for the whole procedure was rated significantly less by means of VAS in the group where the RN was used, irrespective of whether analysed by ITT (mean 21.4 versus 26.0 mm) or PP (mean 21.0 versus 26.0 mm), corresponding to a 19% pain reduction (see Table [II](#DER100TB2){ref-type="table"}). Table IIPrimary end-point, measurements of VAS, mm; mean ± SD (range)RNSN*P*-value95% CIIntention to treat*n*= 129*n*= 127Overall pain during OPU21.4 ± 18.1 (0--78) *n*= 128^a^26.0 ± 19.7 (0--84) *n*= 126^b^0.047−9.24 to 0.11Per population*n*= 126*n*= 124Overall pain during OPU21.0 ± 17.5 (0--78) *n*= 125^a^26.0 ± 19.9(0--84) *n*= 123^b^0.040−9.72 to −0.36[^3][^4][^5][^6]

When adjusted for baseline characteristics, such as number of follicles at last ultrasound scan before OPU, previously performed OPU, BMI and age, by use of a multiple linear regression analysis, there is still significantly less overall pain in the RN group when compared with the SN group (*P* = 0.034).

Secondary end-points of pain variables, maximum pain, pain experience directly after 30 and 60 min after the procedure did not differ between the groups (Table [III](#DER100TB3){ref-type="table"}). Table IIISecondary end-point, measurements of VAS, mm; mean ± SD (range)RN (*n*= 126)SN (*n*= 124)*P*-value95% CIPain directly after OPU13.9 ± 17.3 (0--77)13.3 ± 15.0 (0--74)0.53−3.50 to 4.64Maximum pain after OPU33.6 ± 26.0 (0--96)39.1 ± 24.4 (0--96)0.06−11.81 to 0.79Pain 30 min after OPU17.6 ± 18.6 (0--72)18.0 ± 19.7 (0--98)0.66−5.20 to 4.38Pain 60 min after OPU10.8 ± 13.7 (0--61)11.8 ± 14.3 (0--69)0.27−4.54 to 2.53% patients who requested more i.v. analgesia25.431.50.36−18.3 to 6.40% patients with \<30 mm on VAS in overall pain during OPU70.461.00.14−0.31 to 0.22[^7][^8]

Secondary end-points {#s3b}
--------------------

A significant difference was found between the two groups in the assessment of bleeding (see Table [IV](#DER100TB4){ref-type="table"}). Significantly more patients had less vaginal bleeding than expected when the RN was used, 32% (40 of 126) versus 19% (24 of 124); *P* = 0.029, 95% CI (1.7--23.0%). Table IVSecondary end-points, treatment and outcome variables, ± mean (range) when applicableRN (*n*= 126)SN (*n*= 124)*P*-valueBleeding No. of patients with less than expected bleeding (%)40 (31.7)24 (19.4)0.042 No. of patients with normal bleeding (%)80 (63.5)93 (75.0) No. of patients with more than normal bleeding (%)6 (4.8)7 (5.6)Total OPU time (min)7.72 ± 4.10 (1--22)7.52 ± 3.73 (3--20)0.85Oocyte recovery/follicle (%)77.2 ± 24.273.4 ± 25.40.27No. of mature oocytes7.57 ± 5.31 (0--27)7.34 ± 4.91 (0--27)0.91No. of damage oocytes0.41 ± 1.23 (0--8)0.43 ± 1.20 (0--10)0.67Fertilization rate (%)72.7 ± 25.870.2 ± 26.30.53Cleavage rate^a^ (%)70.8 ± 26.668.5 ± 25.60.50No. of transferred embryos1.06 ± 0.54 (0--2)1.07 ± 0.55 (0--2)0.89No. of frozen embryos1.30 ± 2.04 (0--12)1.28 ± 1.89 (0--8)0.80Proportion of good quality of embryos (%)^b^27.9 ± 20.229.8 ± 23.50.64Implantation rate (%)21.6 ± 42.425.9 ± 44.60.40Clinical pregnancy rate (%)19.824.40.48[^9][^10][^11][^12]

If also adjusting for the above-mentioned baseline characteristics and vaginal bleeding by use of a multiple logistic regression, there is still significantly more patients with less vaginal bleeding than expected in the RN group when compared with the SN group \[*P* = 0.022, 95% CI (0.28--0.90)\].

There were no difference in aspiration time, oocytes recovered, damage to oocytes, fertilization rate, cleavage rate, proportion of good quality embryos, implantation and clinical pregnancy rate between the two groups, as presented in Table [IV](#DER100TB4){ref-type="table"}. Furthermore, there was no difference between the groups with regard to the number of patients who requested more i.v. analgesia (Table [III](#DER100TB3){ref-type="table"}).

No clinically important adverse events were observed in either of the groups.

Discussion {#s4}
==========

The overall pain during oocyte aspiration was significantly reduced in the group with the thinner needle when compared with the SN. The reduction in overall pain as measured by self-assessment on a VAS scale was 19%. Furthermore, significantly more patients had less vaginal bleeding than expected. No negative effects were found in relation to the oocyte or the outcome of the treatment.

Evaluating pain experience during oocyte retrieval is difficult since there are so many factors that influence pain, fear of pain, anxiety, type of analgesia, physician\'s skill and technical factors such as needle diameter and sharpness. These factors have a clear influence on pain threshold ([@DER100C21]), and are therefore a potential source of bias. In this study, one such factor that could be of importance is the fact that the doctor was not blinded to the type of needle. Unfortunately, we found it impossible to blind the doctor as to the needle in use, since the needles are easily distinguishable on the ultrasound screen. This is of course a weakness of the study. Another factor that might introduce bias is the lack of blinding of the study nurses. We consider that this is of minor relevance since the nurse\'s involvement was limited to asking the patient to mark the VAS. The nurse\'s knowledge of which needle was used is thus not believed to influence the patient\'s experience of pain. Furthermore, there is no objective method for evaluating pain.

Despite those problems, several studies have tried to evaluate the patient\'s pain experience during oocyte retrieval, mainly focusing on the method for analgesia.

A Cochrane review of such studies concluded that there is insufficient evidence to determine the best method of pain relief for OPU ([@DER100C12]). It is interesting to note that technical factors such as needle diameter and type of bevel have largely been neglected with regard to pain related to oocyte retrieval. Almost from the start of human IVF, it has been assumed that an 'ideal' follicle aspiration needle should have an inner diameter of at least 0.8 mm, which means that the outer diameter will be between 1.2 and 1.4 mm (16--18 gauge) depending on the wall thickness of the needle ([@DER100C13]). The background for choosing the diameter mentioned above is that such a diameter has, in several studies, proved to result in good recovery rates and a low frequency of damage to oocytes ([@DER100C20]; [@DER100C3]).

Our results with less overall pain experience in the group where the RN was used is supported by a study by Awonuga *et al*., who found a significant reduction in how patients perceived pain when oocyte retrieval needle size was decreased from 15 gauge to either 17 or 18 gauge. However, that study evaluated pain using a questionnaire answered by patients post-operatively and not VAS ([@DER100C1]). In another interesting although small study where VAS was used, it was clearly shown that the patient experienced less pain on the side where a thinner needle (16 versus 18 gauge) was used ([@DER100C2]).

The limit of 30 mm on a VAS is often used for administration of analgesics post-operatively ([@DER100C19]). However, there was no statistically significant difference between patients below 30 mm on the VAS scale in the RN group when compared with the SN group (Table [III](#DER100TB3){ref-type="table"}).

In conclusion, our results indicate that a needle as thin as 20 gauge does result in a reduction of the overall pain as measured by VAS. Furthermore, even though not objectively measured, we also found a significant difference in the number of patients with less than expected vaginal bleeding between the two needles. The lower proportion of patients with less than expected vaginal bleeding indicate that the needle could be less traumatic.

It is reassuring that the thinner needle does not seem to have any negative effects on the cumulus oocyte complex. The reason for this might be that the thinner part of the needle is very short. The low proportion of damaged oocytes in our study is very similar to what has been reported in another prospective randomized controlled study where two different needles were tested ([@DER100C16]); however, larger studies are needed to confirm this finding.

Although, one might expect that a reduction of the inner diameter of the needle by as much as 40% would influence the recovery rate and/or the total aspiration time; however, this was not the case in our study. The reason may be that only a very short part of the needle was reduced.

Very few studies have investigated the importance of the needle design for the oocyte recovery and possible damage to the cumulus oocyte complex in clinical IVF. In studies on bovine oocytes, it has been demonstrated that both the diameter and bevel of the needle, as well as the aspiration vacuum, is important for the recovery rate and developmental competence of the oocyte ([@DER100C6], [@DER100C7]). In this study, human oocytes were unaffected by needles as thin as 20 gauge and an aspiration pressure of 90--120 mmHg.

In conclusion, oocyte aspiration performed with the RN resulted in significantly less overall pain and less vaginal bleeding without prolonging the retrieval procedure or influencing the oocyte recovery rate, compared with a SN. Furthermore, no adverse effects on the oocyte were found, as evaluated by the outcome of the IVF procedure. The thin tip needle, therefore, seems to be advantageous for the patient.
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[^1]: No imbalances were observed among the patient characteristics recorded.

[^2]: OPU, oocyte pick-up.

[^3]: Mann--Whitney *U*-test was used to compare differences in means between the two groups. Calculation of confidence interval of differences in means between the two groups was based on the assumption of normality.

[^4]: OPU, oocyte pick-up.

[^5]: ^a^One patient could not register VAS immediately after OPU owing to severe drop in blood pressure.

[^6]: ^b^One patient did not want to register VAS owing to disappointment about the few oocytes retrieved.

[^7]: Analysis per protocol population. Mann--Whitney *U*-test was used to compare differences in means between the two groups. Calculation of confidence interval of differences in means between the two groups was based on the assumption of normality.

[^8]: OPU, oocyte pick-up.

[^9]: Analysis per protocol population.

[^10]: OPU, oocyte pick-up.

[^11]: ^a^Of normally fertilized.

[^12]: ^b^For definition of good quality of embryos see main text (Materials and Methods).
